Concept: compact dual-hormone patch with stable glucagon

This is an advocacy target, not a product you can buy. It names the engineering bar a real device should clear: put a fully closed, two-hormone loop into roughly the footprint of a single-hormone patch.

Which hormones, and how the second one defends lows. The system delivers insulin to bring glucose down and glucagon — the hormone a healthy pancreas releases to raise glucose — to push it back up. That glucagon channel is what gives an automated loop an active brake against lows, rather than only the passive option of cutting insulin and waiting. In randomized trials, a bihormonal "bionic pancreas" delivering both insulin and glucagon reportedly lowered average glucose and cut time spent low versus insulin-pump therapy, with no carbohydrate counting required.¹² (Amylin is a separate second-hormone path aimed mainly at smoothing post-meal spikes, not at defending lows — this concept is about the glucagon brake.)

Trial outcomes. A fully closed two-hormone loop reached a median 86.6% time in range over two weeks with no meal or exercise announcements at all.³ A one-year real-world study of a fully closed bihormonal system found mean time in range of 80.3%, with median time-below-range of just 1.36%, alongside gains in quality-of-life and diabetes-distress questionnaire scores reported in the study.⁴

The glucagon-stability problem. The reason this isn't already standard is chemistry: native human glucagon is unstable in water and tends to clump and form fibrils, so older bihormonal systems needed fresh glucagon fills.⁵ Dasiglucagon, an engineered analog, stays soluble and stable in a ready-to-use aqueous solution.⁵⁶ It was FDA-approved for severe-hypoglycemia rescue,⁶ and a feasibility study has already run it through a dual-hormone pump — clearing the formulation hurdle that stalled the field.⁷

Device burden of two hormones. Two hormones means two reservoirs, two infusion sets, and two glucose sensors. Today's fully closed bihormonal system is worn as a separate body-mounted unit, with the maker offering a hip bag, belt bag, and special shirt to carry it⁸ — far from a discreet patch. That gap is the concept: the build worth funding is the one that makes the second hormone disappear into the daily footprint people already accept.

Maturity and approvals. No patch-sized bihormonal device is approved anywhere. The closest shipping reference points are insulin-only: the iLet Bionic Pancreas was FDA-cleared in 2023 as an insulin-only system that initializes on body weight and needs no carb counting.⁹¹⁰ A fully closed two-hormone version using a stable glucagon is in active clinical development — Beta Bionics entered a Phase 2a feasibility trial of a bihormonal iLet in Q1 2026 — but nothing is on the market.⁷¹¹

Access. Speculative. A second hormone adds consumable cost and a second supply chain, and pricing for a future device is unknown.

What's coming. The dasiglucagon pivotal that was once planned reportedly never ran. Back on 6 May 2024 Beta Bionics signed an exclusive worldwide collaboration and license agreement with Xeris Biopharma for a pump-stable glucagon formulation,¹² and the Zealand–Beta Bionics dasiglucagon partnership was reported terminated in October 2024.¹³ Those are settled history, not recent news; what is recent is the clinic. The live programme pairs the iLet with that Xeris glucagon, and Beta Bionics reported in April 2026 that it had started a Phase 2a feasibility trial of the bihormonal system in New Zealand in the first quarter of 2026.¹¹ That is a feasibility study, not a registration trial — no filing follows directly from it. A separate fully closed bihormonal system already carries a European CE mark and is in real-world use,⁸ with newer, smaller hardware iterations reported in development. The remaining bar this concept names is the last one: miniaturization — folding that proven two-hormone control into a patch.